Applications. Eppendorf Thermomixer: A low-cost hybridization station for high quality FISH analysis. Note 156 July Abstract.

Size: px
Start display at page:

Download "Applications. Eppendorf Thermomixer: A low-cost hybridization station for high quality FISH analysis. Note 156 July Abstract."

Transcription

1 Applications Note 156 July 2007 Eppendorf Thermomixer: A low-cost hybridization station for high quality FISH analysis. Sascha Eghtessadi, Maria Christina Tsourlakis, Annastasia Tsaklakidis, Silvia Schnöger, and Ronald Simon Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Abstract Fluorescence in situ hybridization (FISH) is the gold standard methodology for gene copy number determination in cultured cells, metaphase spreads, tissue samples or cytologic specimens. While it has primarily been used as a research tool during the last decade, there is a growing demand for the use of FISH as a diagnostic tool. In such a setting, analysis speed, reliability and cost efficiency become important parameters. Perhaps the most critical step in the FISH procedure is the proper adjustment and maintenance of temperatures for DNA denaturation and probe hybridization. We have compared different devices for slide heating to estimate their suitability for FISH analysis. Our study demonstrates that programmable slide incubators are profoundly superior to the classical waterbath for FISH analysis. The Eppendorf add-on hybridization station is an attractive alternative for owners of the Thermomixer comfort device that allows for high-quality FISH analysis at low cost for machinery. Introduction Fluorescence in situ hybridization (FISH) technology is a means to directly visualize defined DNA sequences in cell nuclei of cell preparations, metaphase spreads, or histological tissue sections. FISH is a frequently used technique particularly in biological and medical research, for example to localize genes on chromosomes, map translocation breakpoints, or to determine gene copy numbers [1]. During the last decade FISH has massively gained importance also for medical diagnostics. Primary genetic events like chromosomal translocations, amplifications, or DNA mutations highlight genetic loci of genes with particular importance for cancer development, diagnosis, or therapy. In particular, genes that undergo amplification have proven to be suitable targets for a new class of gene specific anticancer drugs. Probably the bestknown example for a gene that frequently undergoes amplification is the ERBB2 (HER2/neu) transmembrane receptor. Located on chromosome 17q12, ERBB2 encodes a growth factor receptor tyrosine kinase that connects an extracellular growth trigger to an intracellular signal transduction pathway that finally results in cell growth [2]. Although ERBB2 is (except from heart) not expressed in normal human tissues, it is of major importance in breast cancer. About % of advanced breast cancers are characterized by amplification of the genomic region harboring the ERBB2 gene [3]. The amplification usually results in an elongated chromosome with dozens of adjacent ERBB2 gene copies. Since all ERBB2 gene copies are readily translated into protein, ERBB2 amplified cells are characterized by a massive overexpression of the receptor molecule at the cell surface. Because all these ERBB2 molecules are functional and can activate the growth cascade, ERBB2 amplification and overexpression obligatory leads to breast cancer. In 1998, the FDA approved trastuzumab (Herceptin), a monoclonal antibody that binds to the ERBB2 receptor. Clinical studies demonstrated that Herceptin treatment in combination with cytotoxic drugs provides a significant survival benefit for patients with ERBB2 positive breast cancer, making ERBB2 a paradigm for the new class of targeted therapies [4]. These findings have raised the issue of what is the best method for ERBB2 diagnosis in clinical praxis. Early studies used immunohistochemistry to directly detect ERBB2 protein overexpression in tissue sections from breast tumors. Later it was found that an indirect approach analyzing the ERBB2 gene copy number by means of fluorescence in situ hybridization (FISH) is more accurate and better predicts response to Herceptin treatment [5].

2 Application Note 156 Page 2 Introduction The importance of FISH analysis for the emerging field of predictive molecular pathology is steadily growing. Additional genes have been identified that undergo amplification, and that represent targets for existing gene specific therapies (e.g. EGFR) [6], or targets for drugs under development (e.g. AKT) [7]. As a consequence, a growing need for high quality FISH analysis as a tool for medical routine diagnostic can be expected. FISH analysis is a technically challenging procedure. Besides the quality of the probe (which is generally excellent for commercial probes), highly standardized experimental conditions, particularly with respect to denaturation and hybridization temperatures, are crucial for analysis success. This study was designed to address the suitability of a low-cost add-on slide tray to the Eppendorf Thermomixer comfort device for the FISH based detection of ERBB2 amplification in breast cancer tissue samples. Materials and Methods Tissues. For evaluation of ERBB2 amplification, a total of 229 tissue samples were selected from the archive of the Department of Pathology of the University Medical Center Hamburg Eppendorf (Hamburg, Germany). A tissue array (TMA) was constructed from these samples according to the procedure described in Kononen et al [8]. Selected tissues included 171 samples of invasively growing high grade (BRE grade 3) ductal breast cancers that have the highest likelyhood to contain gene amplifications. In addition to the breast cancer samples, 58 control tissues including normal tissue samples of heart (n=2), kidney (n=2), lung (n=2), colon (n=2), endometrium (n=2), prostate (n=2), lymph node (n=2), sceletal muscle (n=2), skin (n=2), breast (n=10), as well as several different neoplastic tissues including lung cancers (n=10), colon cancers (n=10), and prostate cancers were included in the TMA (Figure 1). Fluorescence in situ hybridization. The TMA sections were treated according to the Paraffin Pretreatment Reagent Kit protocol (Vysis, Downers Grove, IL) before hybridization. To study the potential influence of different methods for slide heating and incubation, three experimental setups were tested. The different approaches are listed in Table 1. FISH was performed with a Spectrum Orange-labeled Fig. 1: Hematoxilin-eosin stained section of the tissue microarray. The diameter of each tissue spot is 0.6 mm. A magnification of a single tissue spot is shown in the insert. ERBB2 probe and a Spectrum Green-labeled chromosome 17 centromeric probe as reference (Vysis). Hybridization and posthybridization washes were according to the LSI procedure (Vysis). Slides were then counterstained with 1000 ng/ml 4,6-diamino-2-phenylindole in an antifade solution (Abbott, USA). Tab. 1: Experimental setup Device Vendor Features Capacity Denaturation Incubation ThermoBrite Thermomixer comfort Conventional water bath Abbott Molecular Eppendorf Various vendors Programmable slide incubator Device with heating, sooling and mixing function Can be operated with different exchangeable thermoblocks for various tube formats and slides 2 programmable incubation steps 12 slides in separate trays 4 slides in separate trays Almost unlimited; slides in coplin jars 72 C, 5 min; 10 µl denaturation solution per slide 72 C, 5 min; 10 µl denaturation solution per slide (no mixing) 72 C, 5 min; denaturation solution in coplin jar 37 C, overnight 37 C, overnight (no mixing) 37 C, overnight

3 Application Note 156 Page 3 Materials and Methods FISH scoring. ERBB2 and centromere 7 (Cen7) copy numbers were determined in 20 non-overlapping cell nuclei in each tissue spot using an epifluorescence microscope equipped with filtersets suitable for detection of the spectrum orange and spectrum green labeled FISH probes. Average signal numbers from the 20 cell nuclei were calculated for Cen7 and ERBB2. Amplification was defined as presence of at least two times more average ERBB2 gene signals than average centromere 7 signals. All samples not meeting this criterion were categorized as normal. Results Not all tissue spots were interpretable by FISH analysis (Table 2). Reasons for non-analyzable tissues were first of all related to the TMA technology, i.e. missing spots in the tissue section. The number of available tissue spots was n = 209 for the slides incubated in the ThermoBrite and the Theromixer comfort, and n = 207 in the slide incubated in the waterbath. Another fraction of tissue spots was not analyzable because of lacking FISH signals. Such failure occurred only rarely if the slides were incubated in the ThermoBrite (10/209 analyses failed, 5 %) or in the Thermomixer comfort device (13/209, 6 %). In contrast, more than one third of tissues (63/207, 36 %) did not show FISH signals in the water bath-incubated slide. Accordingly, ERBB2 status was interpretable in 184 tissues (including 153 cancers) pretreated in the ThermoBrite, in 186 tissues (142 cancers) pretreated in the Thermomixer comfort, and in only 134 tissues (89 cancers) that had been incubated using the waterbath. In addition, fluorescence intensity was overall slightly weaker for the slide incubated in the waterbath as compared to ThermoBrite or Theromixer comfort (Figure 2). b c a Fig. 2: Examples of ERBB2 amplification. A) ThermoBrite, B) Thermomixer comfort, C) waterbath However, cases with ERBB2 amplification were readily identified irrespective of the type of slide incubation. Small differences in the overall frequency of ERBB2 amplification in breast cancer tissues (18.3 %, 18.3 %, 22.5 %, respectively) only resulted from the different number of interpretable cases. All results are summarized in Table 2.

4 Application Note 156 Page 4 Results Tab. 2: Influence of different slide incubation devices on the success of HER2-FISH analysis in breast cancer. ThermoBrite Thermomixer comfort Waterbath TMA contents Tissue spots on TMA slide Tumors Controls Studied tissues Spots available for study Successfully analyzed spots Successfully analyzed cancer spots ERBB2 amplification (n) ERBB2 amplification (%) Discussion The results of our study demonstrate that the laboratory equipment used for adjusting and maintaining proper slide temperature has profound influence on the success of FISH analysis. Computer-controlled devices with special slots for microscopic slides are clearly superior over conventional waterbaths. We used a tissue microarray approach to compare analysis results in more than 200 breast tissue samples. TMAs are perfectly suited for such kind of protocol comparisons, because a high number of samples can be simultaneously analyzed under highly standardized conditions. In particular, enzymatic tissue pretreatment, which is a critical step for optimal penetration of the FISH probe into the cell nucleus, was performed simultaneously for the three slides, therefore strictly avoiding any potential experimental bias. In addition, a commercially available, FDA approved ERBB2 FISH probe was used that is optimized for analysis of paraffin-embedded, formalin fixed breast cancer tissues. As expected, FISH results were highly comparable if the ThermoBrite or the Thermomixer comfort device were used for slide heating. Both devices are specifically made for this purpose, and differ mainly only in the capacity. Whereas the Abbott TermoBrite (12 slots) is perfectly suited for medium to large scale FISH analysis (e.g. in routine diagnostic labs), the Eppendorf Thermomixer comfort (4 slots) represents a low cost add-on device that may be wanted by customers already owning a Thermomixer comfort device and whishing to expand the abilities of their labs for occasional high-quality FISH analysis. General availability in labs, as well as a great slide capacity, is an advantage of the waterbath-approach. However, a critical step in FISH analysis is maintenance of the proper temperature of DNA denaturation [9]. Insufficient denaturation usually results in low hybridization efficiency and loss of signal strength, whereas overdenaturation because of too high temperature or excessive denaturation time causes damage to the chromosomes and blurred FISH signals that cannot be properly scored. For denaturation, coplin jars with denaturation solution are put into the water and preheated to 75 C, before the slides are added. According to our own experience, the temperature might drop significantly (2 5 C, depending on the number of slides) in the moment the cold slides are put in. Even in our present study where only one single slide was denatured at a time, this effect resulted in a particularly high fraction (36 %) of non-analyzable tissue spots. In comparison, only 5 6 % nonanalyzable tissue spots where found using the ThermoBrite or Thermomixer comfort. The obvious difficulties in adjusting and maintaining proper temperature, and the risk of considerable additional costs in case of failed analyses that must be repeated using expensive commercial FISH probes, clearly argument against a waterbath as first choice for FISH analysis. Remarkably, presence of ERBB2 amplification was properly identified independently from the method or device used for slide incubation, provided that FISH analysis was successful. Even the use of a suboptimal procedure (i.e. waterbath incubation) merely led to a poor overall success rate of FISH analysis, but did not produce any false positive or false negative results with respect to ERBB2 amplification. This finding illustrates an important advantage of FISH over immunohistochemistry (IHC) for diagnostic ERBB2 analysis. In IHC analysis, non reactive samples inevitably produce a seemingly negative result. This is typically caused by improper tissue fixation or antigen retrieval procedures that prevent antibody binding,

5 Application Note 156 Page 5 Discussion and cannot be distinguished from true negative (lack of protein expression) results. Even the use of positive control tissues or cell lines cannot avoid such misinterpretation, because they merely control for proper processing of the IHC assay, but not for insufficient tissue quality of the test slide. Such false negative results cannot occur in FISH analysis, because tissues lacking any detectable FISH signals will be readily recognized as non-reactive and excluded from analysis. In summary, our study demonstrates that programmable slide incubators are profoundly superior to the classical waterbath for FISH analysis. The Eppendorf add-on hybridization station is an attractive alternative for owners of the Thermomixer comfort device that allows for high-quality FISH analysis at low cost for machinery. References [1] Trask BJ. DNA sequence localization in metaphase and interphase cells by fluorescence in situ hybridization. Methods Cell Biol 1991; 35:3 35. [2] Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986; 319: [3] Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, and McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: [4] Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, and Slamon DJ. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185her2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16: [5] Mass, RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, Leiberman G, and Slamon DJ. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005; 6: [6] Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn PA Jr., Franklin WA, Crowley J, and Gandara DR. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005; 23: [7] Thomas SA, Li T, Woods KW, Song X, Packard G, Fischer JP, Diebold RB, Liu X, Shi Y, Klinghofer V, Johnson EF, Bouska JJ, Olson A, Guan R, Magnone SR, Marsh K, Luo Y, Rosenberg SH, Giranda VL, and Li Q. Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase. Bioorg Med Chem Lett 2006;16: [8] Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, and Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4: [9] Petersen BL, Sorensen MC, Pedersen S, and Rasmussen M. Fluorescence in situ hybridization on formalin-fixed and paraffin-embedded tissue: optimizing the method. Appl Immunohistochem Mol Morphol 2004; 12:

6 Application Note 156 Page 6 Ordering information Description Order no. international Order no. North America Thermomixer comfort (Thermomixer R), without thermoblock V, Hz V, Hz V, Hz Exchangeable thermoblock for 4 slides ThermoBrite is a trademark of Abbott Molecular, Des Plaines, USA Your local distributor: Eppendorf AG Hamburg Germany Tel Fax eppendorf@eppendorf.com Eppendorf North America, Inc. One Cantiague Road, P.O. Box 1019 Westbury, N.Y USA Tel Toll free phone Fax info@eppendorf.com Application Support Europe, International: Tel support@eppendorf.com North America: Tel ext support_na@eppendorf.com Asia, Pacific: Tel support_asiapacific@eppendorf.com Eppendorf is a registered trademark. Order No. AA15 6PW 020/GB1/WEB/0707/NEUH

Priti Lal, MD, 1 Paulo A. Salazar, 1 Clifford A. Hudis, MD, 2 Marc Ladanyi, MD, 1 and Beiyun Chen, MD, PhD 1. Abstract

Priti Lal, MD, 1 Paulo A. Salazar, 1 Clifford A. Hudis, MD, 2 Marc Ladanyi, MD, 1 and Beiyun Chen, MD, PhD 1. Abstract Anatomic Pathology / DUAL- VS SINGLE-COLOR SCORING IN IMMUNOHISTOCHEMICAL AND FISH HER-2 TESTING HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence In Situ Hybridization

More information

CANCER. Clinical Validation of Breast Cancer Predictive Markers

CANCER. Clinical Validation of Breast Cancer Predictive Markers Clinical Validation of Breast Cancer Predictive Markers David Hicks, MD Loralee McMahon, MS, HTL(ASCP) CANCER The human body is composed of billions of highly regulated cells Cancer cells no longer respond

More information

HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer

HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer Original article Annals of Oncology 13: 1398 1403, 2002 DOI: 10.1093/annonc/mdf217 HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer

More information

HER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade

HER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade Anatomic Pathology / HER2/NEU AMPLIFICATION IN BREAST CANCER HER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade Elise R. Hoff, MD, Raymond R. Tubbs, DO, Jonathan L. Myles, MD,

More information

TITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer. CONTRACTING ORGANIZATION: Washington University School of Medicine St.

TITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer. CONTRACTING ORGANIZATION: Washington University School of Medicine St. AD Award Number: DAMD17-99-1-9436 TITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer PRINCIPAL INVESTIGATOR: Jeffrey A. Drebin, M.D., Ph.D. CONTRACTING ORGANIZATION: Washington University School

More information

HER2 ISH (BRISH or FISH)

HER2 ISH (BRISH or FISH) Assessment Run H14 2018 HER2 ISH (BRISH or FISH) Material Table 1. Content of the multi-block used for the NordiQC HER2 ISH assessment, run H14 HER2 IHC* IHC score Dual - SISH** FISH*** FISH*** HER2/chr17

More information

HER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam

HER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam HER2 status assessment in breast cancer Marc van de Vijver Academic Medical Centre (AMC), Amsterdam 13e Bossche Mamma Congres 17 th June 2015 Modern cancer therapies are based on sophisticated molecular

More information

HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer

HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer P A T H O L O G Y HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer For In Vitro Diagnostic Use FDA approved as an aid in the assessment of patients for whom Herceptin TM (trastuzumab) treatment

More information

NEW! Micromanipulator meets microscope. Eppendorf Cell Technology

NEW! Micromanipulator meets microscope. Eppendorf Cell Technology NEW! Micromanipulator meets microscope Eppendorf Cell Technology Eppendorf Systems... Intracytoplasmic sperm injection (ICSI) Intracytoplasmic sperm injection (ICSI), the injection of a single sperm into

More information

Comparison of Immunohistochemical and Fluorescence In Situ Hybridization Assessment of HER-2 Status in Routine Practice

Comparison of Immunohistochemical and Fluorescence In Situ Hybridization Assessment of HER-2 Status in Routine Practice Anatomic Pathology / ASSESSMENT OF HER-2 STATUS Comparison of Immunohistochemical and Fluorescence In Situ Hybridization Assessment of HER-2 Status in Routine Practice Michelle Dolan, MD, 1 and Dale Snover,

More information

Immunohistochemical (IHC) HER-2/neu and Fluorescent- In Situ Hybridization (FISH) Gene Amplification of Breast Cancer in Indian Women

Immunohistochemical (IHC) HER-2/neu and Fluorescent- In Situ Hybridization (FISH) Gene Amplification of Breast Cancer in Indian Women Comparison of IHC and FISH for HER-2/neu Status of Breast Cancer in Indian Women RESEARCH COMMUNICATION Immunohistochemical (IHC) HER-2/neu and Fluorescent- In Situ Hybridization (FISH) Gene Amplification

More information

T he HER2/neu type 1 tyrosine kinase growth factor

T he HER2/neu type 1 tyrosine kinase growth factor 710 ORIGINAL ARTICLE HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis

More information

Approximately one third of all cancer-related deaths in

Approximately one third of all cancer-related deaths in ORIGINAL ARTICLE Comparison Between Epidermal Growth Factor Receptor (EGFR) Gene Expression in Primary Non-small Cell Lung Cancer (NSCLC) and in Fine-Needle Aspirates from Distant Metastatic Sites Cecilia

More information

Breast Cancer Interpretation Guide

Breast Cancer Interpretation Guide Breast Cancer Interpretation Guide UCT D O R P NEW ERBB2/ C E P S ht e ZytoLig lor Prob o C l a u 2D D17S12 ng to the i d r o c c a ting for re-tes idelines 2013 ASCO Gu Breast Cancer Interpretation Guide

More information

Welcome! HER2 TESTING DIAGNOSTIC ACCURACY 4/11/2016

Welcome! HER2 TESTING DIAGNOSTIC ACCURACY 4/11/2016 HER2 TESTING DIAGNOSTIC ACCURACY Can t We Finally Get It Right? Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Seattle, Washington Clinical Professor of Pathology University

More information

HER2/neu Evaluation of Breast Cancer in 2019

HER2/neu Evaluation of Breast Cancer in 2019 HER2/neu Evaluation of Breast Cancer in 2019 A.A. Sahin, M.D. Professor of Pathology and Translation Molecular Pathology Section Chief of Breast Pathology ERBB2 (HER2) Background 185-kDa membrane protein

More information

Evolution of Pathology

Evolution of Pathology 1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy

More information

HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer

HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer P A T H O L O G Y HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer FROM CERTAINTY COMES TRUST For in vitro diagnostic use HER2 CISH pharmdx Kit HER2 CISH pharmdx Kit is intended for dual-color

More information

Product Introduction

Product Introduction Product Introduction Product Codes: HCL026, HCL027 and HCL028 Contents Introduction to HER2 2 HER2 immunohistochemistry 3 Cell lines as controls 5 HER2 Analyte Control DR IHC 7 HER2 Analyte Control DR

More information

Quality in Control. ROS1 Analyte Control. Product Codes: HCL022, HCL023 and HCL024

Quality in Control. ROS1 Analyte Control. Product Codes: HCL022, HCL023 and HCL024 Quality in Control ROS1 Analyte Control Product Codes: HCL022, HCL023 and HCL024 Contents What is ROS1? 2 The Role of ROS1 in Cancer 3 ROS1 Assessment 3 ROS1 Analyte Control Product Details 4 ROS1 Analyte

More information

Instant Quality FISH. The name says it all.

Instant Quality FISH. The name says it all. PRODUCT INFORMATION HER2 IQFISH pharmdx Instant Quality FISH Instant Quality FISH. The name says it all. HER2 IQFISH pharmdx IQ: Instant Quality every time. HER2 IQFISH pharmdx stains of a HER2 non-amplified

More information

Immunohistochemical Determination of HER-2/neu Expression in Invasive Breast Carcinoma

Immunohistochemical Determination of HER-2/neu Expression in Invasive Breast Carcinoma Anatomic Pathology / HER-2/NEU IN BREAST CARCINOMA Immunohistochemical Determination of HER-2/neu Expression in Invasive Breast Carcinoma Russell Vang, MD, 1 Linda D. Cooley, MD, 1 Wilbur R. Harrison,

More information

7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview

7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon

More information

Comparison of in situ hybridization methods for the assessment of HER-2/neu gene amplification status in breast cancer using a tissue microarray

Comparison of in situ hybridization methods for the assessment of HER-2/neu gene amplification status in breast cancer using a tissue microarray reports of practical oncology and radiotherapy 1 7 ( 2 0 1 2 ) 44 49 Available online at www.sciencedirect.com jo u r n al hom epage: http://www.elsevier.com/locate/rpor Original article Comparison of

More information

# Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer

# Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer #1034 - Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer Richard W. Cartun, MS, PhD Andrew Ricci, Jr, MD Department of Pathology Hartford

More information

Symposium article. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data

Symposium article. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data Annals of Oncology 12 (Suppl. I): S57-S62, 2001. 2001 Kluwer Academic Publishers. Primed in the Netherlands. Symposium article Trastuzumab combined with chemotherapy for the treatment of HER2-positive

More information

1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?

1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011? Frequently Asked Questions (FAQs) in regard to Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors 1. Q: What has changed from the draft recommendations

More information

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors Significance of Chromosome Changes in Hematological Disorders and Solid Tumors Size of Components of Human Genome Size of haploid genome 3.3 X 10 9 DNA basepairs Estimated genetic constitution 30,000

More information

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors Significance of Chromosome Changes in Hematological Disorders and Solid Tumors Size of Components of Human Genome Size of haploid genome! Estimated genetic constitution! Size of average chromosome

More information

Personalized Medicine: Lung Biopsy and Tumor

Personalized Medicine: Lung Biopsy and Tumor Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the

More information

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:

More information

Taxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1

Taxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1 Important data from BCIRG 006 Taxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1 in the adjuvant treatment of HER2+ breast

More information

Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies

Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies Journal of Pathology J Pathol 2001; 195: 72 79. DOI: 10.1002 / path.893 Review Article Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies Lukas Bubendorf,

More information

KEY WORDS: Breast carcinoma, c-erbb2, Fluorescent. Mod Pathol 2001;14(11):

KEY WORDS: Breast carcinoma, c-erbb2, Fluorescent. Mod Pathol 2001;14(11): HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ Hybridization Thomas A. Thomson, M.D., Malcolm M. Hayes,

More information

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System

More information

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides

More information

Dako IT S ABOUT TIME. Interpretation Guide. Agilent Pathology Solutions. ALK, ROS1 and RET IQFISH probes (Dako Omnis) MET IQFISH probe (Dako Omnis)

Dako IT S ABOUT TIME. Interpretation Guide. Agilent Pathology Solutions. ALK, ROS1 and RET IQFISH probes (Dako Omnis) MET IQFISH probe (Dako Omnis) INTERPRETATION Dako Agilent Pathology Solutions IQFISH Interpretation Guide ALK, ROS1 and RET IQFISH probes (Dako Omnis) MET IQFISH probe (Dako Omnis) IT S ABOUT TIME For In Vitro Diagnostic Use ALK, ROS1,

More information

Dr. dr. Primariadewi R, SpPA(K)

Dr. dr. Primariadewi R, SpPA(K) Curriculum Vitae Dr. dr. Primariadewi R, SpPA(K) Education : Medical Doctor from UKRIDA Doctoral Degree from Faculty of Medicine University of Indonesia Pathologist Specialist and Consultant from Faculty

More information

PD-L1 Analyte Control DR

PD-L1 Analyte Control DR Quality in Control PD-L1 Analyte Control DR PD-L1_PI_v2 Product Codes: HCL019, HCL020 and HCL021 Contents PD-L1 Analyte Control DR 2 What is PD-L1? 3 The Role of PD-L1 in Cancer 3 PD-L1 Assessment 4 PD-L1

More information

Kristen E. Muller, DO, Jonathan D. Marotti, MD, Vincent A. Memoli, MD, Wendy A. Wells, MD, and Laura J. Tafe, MD

Kristen E. Muller, DO, Jonathan D. Marotti, MD, Vincent A. Memoli, MD, Wendy A. Wells, MD, and Laura J. Tafe, MD AJCP / Original Article Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing Increase in Equivocal Results and Utility of Reflex Immunohistochemistry

More information

Considerable advances in the therapy of breast cancer

Considerable advances in the therapy of breast cancer HER-2/neu Status in Breast Cancer Metastases to the Central Nervous System Kelly C. Lear-Kaul, MD; Hye-Ryoung Yoon, MD; Bette K. Kleinschmidt-DeMasters, MD; Loris McGavran, PhD; Meenakshi Singh, MD Context.

More information

Evaluation of HER2/neu oncoprotein in serum and tissue samples of women with breast cancer: Correlation with clinicopathological parameters

Evaluation of HER2/neu oncoprotein in serum and tissue samples of women with breast cancer: Correlation with clinicopathological parameters Evaluation of HER2/neu oncoprotein in serum and tissue samples of women with breast cancer: Correlation with clinicopathological parameters Mehdi Farzadnia, Naser TayyebiMeibodi, Fatemeh HomayiShandiz,

More information

ABBOTT MOLECULAR ONCOLOGY AND GENETICS

ABBOTT MOLECULAR ONCOLOGY AND GENETICS DESCRIPTOR, 9/12, ALL CAPS ABBOTT MOLECULAR ONCOLOGY AND GENETICS 2015-2016 Product Catalog Area for placed imagery Only use imagery that is relevant to the communication CHOOSE TRANSFORMATION See where

More information

Applications of IHC. Determination of the primary site in metastatic tumors of unknown origin

Applications of IHC. Determination of the primary site in metastatic tumors of unknown origin Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification

More information

Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer

Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer Frederik Holst 1,6, Phillip R Stahl 1,6, Christian Ruiz 2,6, Olaf Hellwinkel 3, Zeenath Jehan 4, Marc Wendland 1, Annette

More information

IT S ABOUT TIME. IQFISH pharmdx Interpretation Guide THREEHOURSTHIRTYMINUTES. HER2 IQFISH pharmdxtm. TOP2A IQFISH pharmdxtm

IT S ABOUT TIME. IQFISH pharmdx Interpretation Guide THREEHOURSTHIRTYMINUTES. HER2 IQFISH pharmdxtm. TOP2A IQFISH pharmdxtm I N T E R P R E TAT I O N IQFISH pharmdx Interpretation Guide TM HER2 IQFISH pharmdxtm TOP2A IQFISH pharmdxtm Breast carcinoma (FFPE) stained with HER2 IQFISH pharmdx Breast carcinoma (FFPE) stained with

More information

AmoyDx TM BRAF V600E Mutation Detection Kit

AmoyDx TM BRAF V600E Mutation Detection Kit AmoyDx TM BRAF V600E Mutation Detection Kit Detection of V600E mutation in the BRAF oncogene Instructions For Use Instructions Version: B3.1 Date of Revision: April 2012 Store at -20±2 o C 1/5 Background

More information

Three Hours Thirty Minutes

Three Hours Thirty Minutes INTERPRETATION HER2 IQFISH pharmdx TM Interpretation Guide Three Hours Thirty Minutes it s about time Breast carcinoma (FFPE) stained with HER2 IQFISH pharmdx Gastric cancer (FFPE) stained with HER2 IQFISH

More information

Molecular Probes Introducing 14 new probes

Molecular Probes Introducing 14 new probes Molecular Probes Introducing 14 new probes Gene and Chromosome Probes Dual Colour ISH INFORM HER2 Dual ISH DNA Probe Cocktail Assay Product Part Number INFORM HER2 Dual ISH DNA Probe Cocktail 800-4422

More information

Raise the limits. Eppendorf Research plus

Raise the limits. Eppendorf Research plus NEW! NEW! Raise the limits Eppendorf Research plus A completely new experience Eppendorf Research plus Eppendorf sets a new standard in pipetting. The ultra light Eppendorf Research plus pipette meets

More information

Comparison of Fluorescence and Chromogenic In Situ Hybridization for Detection of HER-2/neu Oncogene in Breast Cancer

Comparison of Fluorescence and Chromogenic In Situ Hybridization for Detection of HER-2/neu Oncogene in Breast Cancer Anatomic Pathology / HER-2 DETECTION BY CISH IN BREAST CANCER Comparison of Fluorescence and Chromogenic In Situ Hybridization for Detection of HER-2/neu Oncogene in Breast Cancer Deepali Gupta, MD, 1

More information

HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer

HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer Yanjun Hou, MD, PhD, 1 Hiroaki Nitta, PhD, 2 and Zaibo Li, MD, PhD 1 From the

More information

Transform genomic data into real-life results

Transform genomic data into real-life results CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for

More information

Molecular Testing in Lung Cancer

Molecular Testing in Lung Cancer Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans

More information

Journal of Breast Cancer

Journal of Breast Cancer ORIGINAL ARTICLE Journal of Breast Cancer J Breast Cancer 2009 December; 12(4): 235-40 DOI: 10.4048/jbc.2009.12.4.235 Comparison of Silver-Enhanced in situ Hybridization and Fluorescence in situ Hybridization

More information

American Society of Cytopathology Core Curriculum in Molecular Biology

American Society of Cytopathology Core Curriculum in Molecular Biology American Society of Cytopathology Core Curriculum in Molecular Biology American Society of Cytopathology Core Curriculum in Molecular Biology Chapter 6 Fluorescence in situ Hybridization (FISH) Principles

More information

MEDICAL POLICY. Proprietary Information of YourCare Health Plan

MEDICAL POLICY. Proprietary Information of YourCare Health Plan MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,

More information

NIH Public Access Author Manuscript Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2011 January 1.

NIH Public Access Author Manuscript Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2011 January 1. NIH Public Access Author Manuscript Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2010 January ; 19(1): 144 147. doi:10.1158/1055-9965.epi-09-0807. Feasibility Study for Collection

More information

Comparative Analysis of Methods Used in Breast Cancer HER2 and Sentinel Lymph Node Diagnosis

Comparative Analysis of Methods Used in Breast Cancer HER2 and Sentinel Lymph Node Diagnosis SHORT THESIS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY (Ph.D.) Comparative Analysis of Methods Used in Breast Cancer HER2 and Sentinel Lymph Node Diagnosis by Monika Francz MD Supervisor: Zoltán Szöllősi

More information

Vysis ALK Break Apart FISH Probe Kit

Vysis ALK Break Apart FISH Probe Kit Vysis ALK Break Apart FISH Probe Kit 06N38 30-608521/R1 Key to Symbols Used Global Trade Item Number Manufacturer Reference Number Lot Number In Vitro Diagnostic Medical Device Contains sufficient for

More information

CME/SAM. Abstract. Anatomic Pathology / HER2/neu Results in Breast Cancer

CME/SAM. Abstract. Anatomic Pathology / HER2/neu Results in Breast Cancer Anatomic Pathology / HER2/neu Results in Breast Cancer Effect of Ischemic Time, Fixation Time, and Fixative Type on HER2/neu Immunohistochemical and Fluorescence In Situ Hybridization Results in Breast

More information

Educator Navigation Guide

Educator Navigation Guide Decoding Breast Cancer Virtual Lab Educator Navigation Guide Decoding Cancer Nav Guide 2 Introduction In this virtual lab, students test tissue samples from different patients with breast cancer in order

More information

VDx: Unlocking Complex Diagnostics

VDx: Unlocking Complex Diagnostics VDx: Unlocking Complex Diagnostics VDx now offers PARR testing in-house on formalin-fixed tissue Complicated Case? Is this cat s chronic lymphocytic enteritis really chronic IBD or is this early small

More information

Targeting the Oncogenic Pathway as Opposed to the Primary Tumor Site: HER2 as an Example

Targeting the Oncogenic Pathway as Opposed to the Primary Tumor Site: HER2 as an Example Targeting the Oncogenic Pathway as Opposed to the Primary Tumor Site: HER2 as an Example Dennis J Slamon, MD, PhD Professor of Medicine Chief, Division of Hematology/Oncology; Director of Clinical/Translational

More information

The role of p95her2 in trastuzumab resistance in breast cancer

The role of p95her2 in trastuzumab resistance in breast cancer JBUON 2016; 21(2): 382-389 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE The role of p95her2 in trastuzumab resistance in breast cancer Nuket

More information

Quality in Control ALK-Lung Analyte Control (EML4-ALK) ALK-Lymphoma Analyte Control (NPM-ALK)

Quality in Control ALK-Lung Analyte Control (EML4-ALK) ALK-Lymphoma Analyte Control (NPM-ALK) Quality in Control ALK-Lung Analyte Control (EML4-ALK) ALK-Lymphoma Analyte Control (NPM-ALK) 10 Product Codes: HCL007, HCL008 and HCL009 HCL010, HCL011 and HCL012 Page 1 of Contents 1. What is ALK?...

More information

MEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association

MEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 7 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product,

More information

Layered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue

Layered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue Page 1 The need for multiplex detection of tissue biomarkers. There is a constant and growing demand for increased biomarker analysis in human tissue specimens. Analysis of tissue biomarkers is key to

More information

Enhanced Accuracy and Reliability of HER-2/neu Immunohistochemical Scoring Using Digital Microscopy

Enhanced Accuracy and Reliability of HER-2/neu Immunohistochemical Scoring Using Digital Microscopy Anatomic Pathology / HER-2 IMMUNOHISTOCHEMICAL SCORING RELIABILITY Enhanced Accuracy and Reliability of HER-2/neu Immunohistochemical Scoring Using Digital Microscopy Kenneth Bloom, MD, 1 and Douglas Harrington,

More information

In Situ Hybridization: Market Strategies and Forecasts, US,

In Situ Hybridization: Market Strategies and Forecasts, US, In Situ Hybridization: Market Strategies and Forecasts, US, 2018-2024 Table of Contents In Situ Hybridization: Executive Summary The study is designed to give a comprehensive overview of the In Situ Hybridization

More information

Technical Advance. Chromogenic in Situ Hybridization

Technical Advance. Chromogenic in Situ Hybridization American Journal of Pathology, Vol. 157, No. 5, November 2000 Copyright American Society for Investigative Pathology Technical Advance Chromogenic in Situ Hybridization A Practical Alternative for Fluorescence

More information

Eppendorf Research plus. Raise the limits NEW! Order no. A /GB4/10T/1109/FEEL/PRINT64 Printed in Germany

Eppendorf Research plus. Raise the limits NEW!  Order no. A /GB4/10T/1109/FEEL/PRINT64 Printed in Germany www.eppendorf.com/research-plus Your local distributor: www.eppendorf.com/worldwide Eppendorf AG 22331 Hamburg Germany Tel: +49 40 538 01-0 Fax: +49 40 538 01-556 E-mail: eppendorf@eppendorf.com Eppendorf

More information

Interpretation Guide. Product Name: ALK Cell Line Analyte Control Product Codes: ALK2/CS and ALK2/CB. Page 1 of 9

Interpretation Guide. Product Name: ALK Cell Line Analyte Control Product Codes: ALK2/CS and ALK2/CB. Page 1 of 9 Interpretation Guide Product Name: ALK Cell Line Analyte Control Product Codes: ALK2/CS and ALK2/CB ALK2/CS/CB_IG_V_001 www.histocyte.com Page 1 of 9 Contents 1. What is ALK?... 2 2. Role of ALK in Cancer...

More information

Role of FISH in Hematological Cancers

Role of FISH in Hematological Cancers Role of FISH in Hematological Cancers Thomas S.K. Wan PhD,FRCPath,FFSc(RCPA) Honorary Professor, Department of Pathology & Clinical Biochemistry, Queen Mary Hospital, University of Hong Kong. e-mail: wantsk@hku.hk

More information

Oncology Genetics: Cytogenetics and FISH 17/09/2014

Oncology Genetics: Cytogenetics and FISH 17/09/2014 Oncology Genetics: Cytogenetics and FISH 17/09/2014 Chris Wragg Head of Oncology Genomics, BGL BGL Bristol Genetics Laboratory (BGL) CPA accredited Genetics laboratory serving a core population of 4-5million

More information

Accepted 7 December 2006 Published online 11 June 2007 in Wiley InterScience (www.interscience.wiley.com). DOI: /hed.20614

Accepted 7 December 2006 Published online 11 June 2007 in Wiley InterScience (www.interscience.wiley.com). DOI: /hed.20614 ORIGINAL ARTICLE SALIVARY DUCT CARCINOMA: A CLINICAL AND HISTOLOGIC REVIEW WITH IMPLICATIONS FOR TRASTUZUMAB THERAPY Vishad Nabili, MD, 1 Jesse W. Tan, MD, 1 Sunita Bhuta, MD, 2 Joel A. Sercarz, MD, 1

More information

Impact of Polysomy 17 on HER-2/neu Immunohistochemistry in Breast Carcinomas without HER-2/neu Gene Amplification

Impact of Polysomy 17 on HER-2/neu Immunohistochemistry in Breast Carcinomas without HER-2/neu Gene Amplification Journal of Molecular Diagnostics, Vol. 5, No. 3, August 2003 Copyright American Society for Investigative Pathology and the Association for Molecular Pathology Impact of Polysomy 17 on HER-2/neu Immunohistochemistry

More information

DETERMINATION OF K-RAS MUTATION IN COLORECTAL AND LUNG CANCER

DETERMINATION OF K-RAS MUTATION IN COLORECTAL AND LUNG CANCER 665 J App Pharm 03(04): 655-669; October, 2012 Andreas et al., 2012 Short Communication DETERMINATION OF K-RAS MUTATION IN COLORECTAL AND LUNG CANCER E.Andreas 1,2,3, Ali Mujahid 1,3, Attia Youssef 1,

More information

Next-Generation Immunohistochemistry: Multiplex tissue imaging with mass cytometry

Next-Generation Immunohistochemistry: Multiplex tissue imaging with mass cytometry Nat Met, April 2014 Nat Med, April 2014 Next-Generation Immunohistochemistry: Multiplex tissue imaging with mass cytometry Journal Club Timo Böge Overview Introduction Conventional Immunohistochemistry

More information

(51) Int Cl.: C12Q 1/68 ( ) C07H 21/04 ( )

(51) Int Cl.: C12Q 1/68 ( ) C07H 21/04 ( ) (19) TEPZZ_7_ Z9B_T (11) EP 1 71 9 B1 (12) EUROPEAN PATENT SPECIFICATION () Date of publication and mention of the grant of the patent: 22.07.1 Bulletin 1/ (21) Application number: 07989.0 (22) Date of

More information

Statistical Analysis of Biomarker Data

Statistical Analysis of Biomarker Data Statistical Analysis of Biomarker Data Gary M. Clark, Ph.D. Vice President Biostatistics & Data Management Array BioPharma Inc. Boulder, CO NCIC Clinical Trials Group New Investigator Clinical Trials Course

More information

Assessment Run B HER2 IHC

Assessment Run B HER2 IHC Assessment Run B26 208 HER2 IHC Material The slide to be stained for HER2 comprised the following 5 materials: IHC: HER2 Score* (0, +, 2+, 3+) FISH: HER2 gene/chr 7 ratio**. Breast carcinoma, no. 2+..3

More information

HER-2/neu Analysis in Gastroesophageal and Gastric Adenocarcinoma Keith Daniel Bohman, MD

HER-2/neu Analysis in Gastroesophageal and Gastric Adenocarcinoma Keith Daniel Bohman, MD HER-2/neu Analysis in Gastroesophageal and Gastric Adenocarcinoma Keith Daniel Bohman, MD Carcinoma of the stomach is the fourth most common cancer and second most frequent cause of cancer-related mortality

More information

HER2 status in breast cancer: experience of a Spanish National Reference Centre

HER2 status in breast cancer: experience of a Spanish National Reference Centre Clin Transl Oncol (2011) 13:000-000 DOI RESEARCH ARTICLES HER2 status in breast cancer: experience of a Spanish National Reference Centre Marta Cuadros Carlos Cano Francisco Javier López Paloma Talavera

More information

1.5. Research Areas Treatment Selection

1.5. Research Areas Treatment Selection 1.5. Research Areas Cancer biomarker research embraces many areas of study, including tumorigenesis, metastasis, clinical trial and surrogate endpoints, cell isolation, target identification, drug resistance,

More information

Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast International Group (BIG aisbl), Chair ESMO President

Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast International Group (BIG aisbl), Chair ESMO President Symposium «Evaluation of the Belgian Cancer Plan» Brussels, November 26th, 2012 Personalized oncology in Europe: only a dream if national health systems do not get involved in diagnostics and pivotal cancer

More information

Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy

Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Cystectomy Contact the GenomeDx Customer Support Team 1.888.792.1601 (toll-free) customersupport@genomedx.com

More information

Assessment of Her-2/neu Overexpression in Primary Breast Cancers and Their Metastatic Lesions: An Immunohistochemical Study

Assessment of Her-2/neu Overexpression in Primary Breast Cancers and Their Metastatic Lesions: An Immunohistochemical Study Annals o f Clinical & Laboratory Science, vol. 30, no. 3, 2000 259 Assessment of Her-2/neu Overexpression in Primary Breast Cancers and Their Metastatic Lesions: An Immunohistochemical Study Shahla Masood

More information

A View to the Future: The Development of Targeted Therapy for Melanoma. Michael Davies, M.D., Ph.D.

A View to the Future: The Development of Targeted Therapy for Melanoma. Michael Davies, M.D., Ph.D. A View to the Future: Science to Survivorship Symposium September 26, 2009 The Development of Targeted Therapy for Melanoma Michael Davies, M.D., Ph.D. Assistant Professor, Melanoma Medical Oncology How

More information

Determination of HER2 Amplification by In Situ Hybridization. When Should Chromosome 17 Also Be Determined?

Determination of HER2 Amplification by In Situ Hybridization. When Should Chromosome 17 Also Be Determined? Anatomic Pathology / FISH f o r HER2: Wh e n to Use Ch r o m o s o m e 17 Determination of HER2 Amplification by In Situ Hybridization When Should Chromosome 17 Also Be Determined? John M.S. Bartlett,

More information

HER-2 Protein Overexpression in Metastatic Breast Carcinoma Found at Autopsy

HER-2 Protein Overexpression in Metastatic Breast Carcinoma Found at Autopsy HER-2 Protein Overexpression in Metastatic Breast Carcinoma Found at Autopsy Shigeya Kyoda 1, Satoki Kinoshita 2, Hiroshi Takeyama 1, Ken Uchida 2 and Toshiaki Morikawa 2 1 Department of Surgery, Jikei

More information

Instructions for Use. APO-AB Annexin V-Biotin Apoptosis Detection Kit 100 tests

Instructions for Use. APO-AB Annexin V-Biotin Apoptosis Detection Kit 100 tests 3URGXFW,QIRUPDWLRQ Sigma TACS Annexin V Apoptosis Detection Kits Instructions for Use APO-AB Annexin V-Biotin Apoptosis Detection Kit 100 tests For Research Use Only. Not for use in diagnostic procedures.

More information

Molecular biomarker profile of EGFR copy number, KRAS and BRAF mutations in colorectal carcinoma

Molecular biomarker profile of EGFR copy number, KRAS and BRAF mutations in colorectal carcinoma ORIGINAL ARTICLE Molecular biomarker profile of EGFR copy number, KRAS and BRAF mutations in colorectal carcinoma Rong Rong, Jamie Tull, Shengle Zhang Department of Pathology, SUNY Upstate University,

More information

The estimation of tumor cell percentage for molecular testing by pathologists is not accurate

The estimation of tumor cell percentage for molecular testing by pathologists is not accurate 168 & 2014 USCAP, Inc All rights reserved 0893-3952/14 $32.00 The estimation of tumor cell percentage for molecular testing by pathologists is not accurate Alexander JJ Smits 1,2, J Alain Kummer 1, Peter

More information

T here are convincing data to support the hypothesis that a

T here are convincing data to support the hypothesis that a 367 ORIGINAL ARTICLE Status of the p53, p16, RB1, and HER-2 genes and chromosomes 3, 7, 9, and 17 in advanced bladder cancer: correlation with adjacent mucosa and pathological parameters M Gallucci, F

More information

Comparative genomic hybridization of primary skeletal Ewing's sarcoma

Comparative genomic hybridization of primary skeletal Ewing's sarcoma Turkish Journal of Cancer Vol.31/ No. 1/2001 Comparative genomic hybridization of primary skeletal Ewing's sarcoma İBRAHİM KESER 1, ELISABETH BURCKHARDT 2, NURDAN TUNALI 3, MUALLA ALKAN 2 1 Department

More information

Concise Reference. HER2 Testing in Breast Cancer. Mary Falzon, Angelica Fasolo, Michael Gandy, Luca Gianni & Stefania Zambelli

Concise Reference. HER2 Testing in Breast Cancer. Mary Falzon, Angelica Fasolo, Michael Gandy, Luca Gianni & Stefania Zambelli Concise Reference Testing in Breast Cancer Mary Falzon, Angelica Fasolo, Michael Gandy, Luca Gianni & Stefania Zambelli Extracted from Handbook of -Targeted Agents in Breast Cancer ublished by Springer

More information

Disclosures Genomic testing in lung cancer

Disclosures Genomic testing in lung cancer Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing

More information

Biochemistry of Cancer and Tumor Markers

Biochemistry of Cancer and Tumor Markers Biochemistry of Cancer and Tumor Markers The term cancer applies to a group of diseases in which cells grow abnormally and form a malignant tumor. It is a long term multistage genetic process. The first

More information

FAQs for UK Pathology Departments

FAQs for UK Pathology Departments FAQs for UK Pathology Departments This is an educational piece written for Healthcare Professionals FAQs for UK Pathology Departments If you would like to discuss any of the listed FAQs further, or have

More information